Intrinsic factor

Intrinsic Factor (Gastric Intrinsic Factor, GIF / CBLIF)

1. Identity, Chemical Nature, and Common Names

Intrinsic factor (IF), also known as cobalamin binding intrinsic factor, or gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells (in humans) or chief cells (in rodents) of the stomach. In the supplement and clinical literature it may also be listed under the gene designations GIF (the older symbol) or CBLIF (the current HGNC-approved symbol). In humans, the gastric intrinsic factor protein is encoded by the GIF gene.

As a dietary supplement or pharmaceutical preparation, intrinsic factor is most commonly isolated from animal sources rather than synthesised synthetically. Concentrates of intrinsic factor derived from hog gastric, pyloric, and duodenal mucosa have been used successfully in patients who lack intrinsic factor. Porcine intrinsic factor is typically isolated from the tissue of the duodenum of a hog (Sus scrofa). IF is secreted by the parietal cells of the stomach in humans, cats, guinea pigs, and monkeys, by the chief cells in rats and mice, and by duodenal and pyloric mucous cells in the hog.

In terms of molecular architecture, intrinsic factor is a glycoprotein composed of a single polypeptide chain consisting of approximately 399 amino acids, with a molecular mass of about 60 kDa, including roughly 15% carbohydrate by mass. The carbohydrate component arises from N-linked oligosaccharide chains attached at multiple asparagine residues, including sites at Asn311, Asn330, Asn334, and Asn413; these include high-mannose and complex types that are essential for the protein's stability and efficient secretion. Human intrinsic factor is a monomer with a two-domain architecture consisting of an N-terminal α-domain and a C-terminal β-domain featuring an α6/β5 TIM barrel that forms a high-affinity binding site for cobalamin.

At the genetic level, intrinsic factor is synthesised exclusively in the parietal cells of the gastric mucosa through the transcription of the GIF (also known as CBLIF) gene, located on chromosome 11q12.1. This gene encodes a precursor protein, prepro-intrinsic factor, with a molecular weight of approximately 50 kDa, which is translated on ribosomes associated with the rough endoplasmic reticulum. The precursor undergoes initial processing via cleavage of an N-terminal signal peptide, directing it into the lumen of the endoplasmic reticulum for further modification. Glycosylation, primarily involving N-linked oligosaccharides, occurs in the endoplasmic reticulum and Golgi apparatus, yielding the mature glycoprotein form critical for stability and function.

2. Natural Source and Cellular Origin

Parietal cells (also known as oxyntic cells) are epithelial cells in the stomach that secrete hydrochloric acid (HCl) and intrinsic factor. These cells are located in the gastric glands found in the lining of the fundus and body regions of the stomach. Its concentration does not correlate with the amount of HCl or pepsin in the gastric juice; intrinsic factor may be present even when pepsin is largely absent.

The primary cellular source in humans is well established, though research has revealed some nuance. Gastric parietal cells have been accepted as the only site of intrinsic factor production in the human stomach. In animals, however, intrinsic factor has been localised to various other cell types of foregut origin, including chief and enteroendocrine cells in gastric mucosa, and duct cells. A study using recombinant human intrinsic factor antiserum demonstrated that most positively stained cells were gastric parietal cells, but at the margins of the anatomical regions (e.g., cardia/fundus, body/antrum) clusters of gastric chief cells and individual enteroendocrine cells were found to contain intrinsic factor.

Secretion of intrinsic factor by parietal cells is stimulated by several physiological signals. IF secretion is stimulated by histamine, pentagastrin, and cholinergic drugs and is inhibited by H2 receptor antagonists (but not omeprazole), prostaglandins, somatostatin, and epidermal growth factor. IF secretion appears to be independent of acid or enzyme secretion.

Regarding the evolutionary context of intrinsic factor, in its journey, three binding proteins transport cobalamin until it reaches the final destination: haptocorrin, intrinsic factor, and transcobalamin II (TC-II). All three genes show homology, indicating total or partial gene duplication of an ancestral gene. All three Cbl-binding proteins share the primary protein structure. In terms of Cbl specificity, intrinsic factor is the highest, and haptocorrin is the least specific.

3. Historical Discovery and Traditional/Historical Use

Discovered in 1929 by William Bosworth Castle through experiments demonstrating the interaction between a gastric component and an extrinsic dietary factor (later identified as vitamin B12), intrinsic factor was named for its endogenous origin in the stomach. The demonstration, in 1929, that normal human gastric juice contained an "intrinsic factor" that, given simultaneously with an "extrinsic factor" present in beef muscle, caused an erythropoietic response in pernicious anemia initiated a laborious form of clinical investigation.

Enveloping Castle's discovery were prevalent ideas in the medical community of the time, such as the importance of nutritional factors in the pathogenesis of disease, and the intriguing possibility that many disorders could be ameliorated or even cured by administration of a "missing" substance. When viewed in a contemporary perspective, Castle's observations of a half century ago are remarkable examples of ingenuity and single-minded dedication to uncovering the pathogenetic mechanism of a previously fatal disorder.

When, in 1948, it was shown that the active principle of purified liver extracts, vitamin B12, was also the so-called extrinsic factor, interest quickened. In 1934, the Nobel Prize for Physiology and Medicine was awarded to George Hoyt Whipple, George Richards Minot, and William Parry Murphy for work based on the initial work of Castle and for discovering the cure for pernicious anemia.

Before intrinsic factor was understood at a molecular level, the clinical application of gastric tissue preparations to treat pernicious anemia constituted the first therapeutic use. Fouts et al. maintained patients with pernicious anemia in clinical remission with oral therapy (liver extracts or intrinsic factor concentrate with vitamin B12) for as long as 29 years. In the treatment of pernicious anemia, it was necessary either to administer vitamin B12 parenterally or to add intrinsic factor to the vitamin B12 given by mouth to ensure proper absorption. These historical preparations represented the first systematic, medically documented use of intrinsic factor as an interventional agent, predating the isolation and characterisation of vitamin B12 itself.

There is no pre-scientific traditional botanical or folk medicine use of intrinsic factor per se; its role was unknown until the twentieth century. However, the empirical observation that feeding liver to patients with pernicious anemia (which had been a fatal disease) could restore blood counts and reverse symptoms — a practice dating from the work of Minot and Murphy in 1926 — provided the clinical context in which Castle's mechanistic discovery was made. Liver is now known to be rich in both vitamin B12 and in factors that support gastric health.

4. Key Constituents and Mechanisms of Action

4.1 Molecular Identity

In addition to hydrochloric acid, the parietal cells in the gastric mucosa secrete intrinsic factor, a 49-kDa glycoprotein that binds to vitamin B12 (cyanocobalamin) and is necessary for its absorption from the small intestine. Intrinsic factor is a glycoprotein that contains 15% carbohydrate and is secreted by the parietal cells of the body and fundus of the stomach.

The N-terminal domain (alpha-domain) consists of alpha-helices linked by a single flexible linker, to the C-terminal domain (beta-domain) which consists of beta-helices. The beta-domain side chains composition is a determinant of the specificity of ligand binding.

4.2 The Multi-Step Absorption Cascade

Intrinsic factor operates as part of a sequential, multi-step physiological transport system for vitamin B12:

• Step 1 — Gastric liberation: The journey of vitamin B12 absorption begins in the stomach, where the vitamin is first freed from the proteins in the food we eat. Stomach acid, specifically hydrochloric acid, and the digestive enzyme pepsin work together to break the bonds holding B12 to its dietary carrier proteins.
• Step 2 — Initial binding to haptocorrin: Cobalamin binds the first Cbl-binding protein haptocorrin (HC) in the stomach, following Cbl separation from the protein of food, to form the Cbl-HC complex. IF does not immediately bind to B12 because the R-protein has a higher affinity for the vitamin in the acidic gastric environment.
• Step 3 — Transfer to intrinsic factor: Although intrinsic factor is synthesised and secreted in the acidic environment of the stomach, it binds with B12 at an optimum pH of approximately 7. Vitamin B12 is initially bound by haptocorrin (R factor); after which exposure to the higher pH and proteolytic enzymes of the duodenum dissociate the haptocorrin–B12 complex and allows for intrinsic factor binding.
• Step 4 — Ileal absorption via the cubam receptor: The B12-IF complex reaches the terminal ileum, where it binds to heterodimeric receptors cubam composed of an outer protein cubilin and transmembrane protein amnionless, located on the surface of polarised epithelial enterocytes in the apical brush border. Upon reaching the terminal ileum, the intrinsic factor–B12 complex is endocytosed by specialised epithelial cells.
• Step 5 — Intracellular processing and export: Inside the cells, vitamin B12 dissociates once again and binds to another protein, transcobalamin II; the new complex can then exit the epithelial cells to be carried to the liver.

Thus bound, intrinsic factor protects vitamin B12 from digestion as it passes through the gastrointestinal tract and facilitates the vitamin's absorption in the ileum of the small intestine.

4.3 Physiological Functions Enabled by Intrinsic Factor

The functions attributed to intrinsic factor are entirely mediated through its enabling of adequate vitamin B12 absorption. Once absorbed, B12 is used as a cofactor for enzymes that are involved in the synthesis of deoxyribonucleic acid (DNA), fatty acids, and myelin. More specifically, vitamin B-12 serves as an essential cofactor for two biochemical reactions. In the form of methyl-B12, it assists in folate-dependent conversion of homocysteine to methionine catalysed by methionine synthase. In the form of adenosyl-B12, it assists in the conversion of methylmalonyl-CoA to succinyl-CoA as an intermediate step in odd-chain fatty acid oxidation and ketogenic amino acid catabolism. When vitamin B-12 is deficient, homocysteine and methylmalonic acid accumulate in the cell and are exported into the blood. Thus, elevations in homocysteine and methylmalonic acid in plasma or serum are functional indicators of vitamin B-12 deficiency.

The limited amount of normal human gastric intrinsic factor limits normal efficient absorption of B12 to about 2 μg per meal, a nominally adequate intake of B12. The average daily diet in Western countries contains 5 to 30 μg vitamin B12, of which 1 to 5 μg is absorbed. The total body stores of the vitamin in adults range from 2 to 5 mg, of which approximately 1 mg is found in the liver.

5. Scientific Evidence by Area of Use

5.1 Pernicious Anemia and Autoimmune Intrinsic Factor Deficiency

Pernicious anemia is a complex disease with a clear autoimmune basis. The anemia is megaloblastic and is caused by vitamin B12 deficiency secondary to intrinsic factor (IF) deficiency. Pernicious anemia is an autoimmune disorder that occurs due to autoantibodies directed against IF or gastric parietal cells (that produce IF). Two distinct antibody subtypes are recognised: Type 1 antibodies are directed against the cobalamin binding site on IF. Type 2 acts against the ileal mucosal receptor.

It has been estimated that the prevalence of pernicious anemia in European countries is approximately 4% of the population. Absolute deficiency of B12 occurs in up to 6% of those aged 60 years and older, whereas marginal deficiency occurs in close to 20% of patients in later life.

The standard treatment for pernicious anemia historically relied on bypassing the defective IF-mediated absorption pathway. Many patients with pernicious anemia are treated with lifelong intramuscular (IM) vitamin B12 replacement. As early as the 1950s, there were studies suggesting that oral vitamin B12 replacement may provide adequate absorption. It is believed that oral vitamin B12 can be absorbed passively, independent of intrinsic factors.

A 2016 systematic review published in Frontiers in Medicine (PMC) identified two randomised controlled trials, three prospective papers, one systematic review, and three clinical reviews meeting inclusion criteria. Relevant articles were identified by PubMed search from January 1, 1980 to March 31, 2016 and through hand search of relevant reference articles. Two randomised controlled trials, three prospective papers, one systematic review, and three clinical reviews fulfilled the inclusion criteria. The review found that oral vitamin B12 replacement at 1000 mcg daily was adequate to replace vitamin B12 levels in patients with pernicious anemia.

A 2024 prospective cohort study published in the American Journal of Clinical Nutrition examined oral cyanocobalamin supplementation (1000 μg/day) in 26 patients with confirmed pernicious anemia. Vitamin B12 deficiency was corrected within 1 month of oral vitamin B12 supplementation in 23 of the 26 (88.5%) patients, and all participants had their deficiency corrected by the end of the follow-up. No difference was observed between the PA-IFA (anti-intrinsic factor antibody-positive) and PA-APCA (anti-parietal cell antibody-positive without IFA) groups. After just 1 month of supplementation, 9 of the 10 (90.0%) patients in the PA-IFA group and 14 of the 16 (87.5%) patients in the PA-APCA group no longer had vitamin B12 deficiency. This evidence supports the concept that passive absorption of high-dose oral B12 can compensate for IF deficiency.

Evidence strength: The evidence that IF is essential for physiological B12 absorption is robust and mechanistically well-established. The evidence that high-dose oral B12 can bypass IF deficiency in pernicious anemia is supported by multiple prospective studies and at least two RCTs, though the total evidence base remains limited in scale.

5.2 Hematological Effects: Megaloblastic/Macrocytic Anemia

Intrinsic factor plays a crucial role in the transportation and absorption of the vital micronutrient vitamin B12 (cobalamin) by the terminal ileum. Insufficiency of intrinsic factor could lead to devastating consequences on body homeostasis. The effect ranges from hematological to neurological disorders and, in unfortunate cases, fatal cardiovascular disease.

Vitamin B12 is necessary for red blood cell maturation. A lack of intrinsic factor may result in inadequate absorption of the vitamin and cause pernicious anemia. Once diagnosed, prompt treatment with B12 supplementation commonly reverses the patient's anemia; however, they will require lifelong supplementation and monitoring.

The historical evidence for oral intrinsic factor concentrate preparations in maintaining patients in remission from pernicious anemia is clinical rather than from modern RCTs. After total gastrectomy, Ficarra found multifactor preparations taken orally to be just as effective in maintaining blood levels as any medication that has to be administered parenterally. His study was based on 24 patients who had survived for 5 years after total gastrectomy for cancer and who had been taking 2 capsules daily.

Evidence strength: Strong mechanistic and clinical evidence links IF deficiency to megaloblastic anemia; treatment with B12 (either via IF-mediated or passive absorption) is well-established. Evidence specifically evaluating oral IF concentrate supplementation (rather than high-dose oral B12) as a therapeutic agent is limited to older, small, non-randomised studies.

5.3 Neurological Function

Pernicious anemia is generally considered to be a heredofamilial disease in which a lack of intrinsic factor is associated with atrophy of the gastric mucosa. As the disease develops, intrinsic factor production decreases and then ends; vitamin B12 in physiologic amounts then cannot be transported across the intestinal mucosa, and the tissue stores of the vitamin are gradually depleted and eventually exhausted. Severe B12 deficiency results in the myelin sheath wasting away and is a potential complication of pernicious anemia. It commonly presents with sensory deficits, paraesthesia, weakness, ataxia (lack of coordination), and gait disturbance.

When the disease remains undiagnosed and untreated for an extended period, it may lead to neurological complications, gastric cancer, and even fatal anemia. Vitamin B12 deficiency can lead to a spectrum of clinical manifestations, ranging from fatigue, lethargy, and pallor to neurological symptoms such as numbness, tingling, gait disturbances, and cognitive impairment. In severe cases, it can result in megaloblastic anemia, peripheral neuropathy, and irreversible neurological damage.

Evidence for neurological reversal after diagnosis and B12 replacement has been documented in case-level and cohort data, including in the context of congenital syndromes. Dementia and sensorimotor deficits leading to paralysis responded remarkably to treatment, despite the late diagnosis.

Evidence strength: Mechanistic evidence is strong; reversal of neurological symptoms with B12 repletion after IF-deficiency correction is well-documented in case series and cohort studies. No RCT evidence specifically tests intrinsic factor supplementation as a neurological intervention independent of its effect on B12 absorption.

5.4 Congenital Intrinsic Factor Deficiency

Mutations in the GIF gene are responsible for a rare inheritable disease called intrinsic factor deficiency, which results in malabsorption of vitamin B12. This is distinct from autoimmune (acquired) pernicious anemia. Sequencing of all the exons of the GIF gene in patients with intrinsic factor deficiency (IFD) identified a single-nucleotide substitution at position 2 of codon 5 (68A-G) in 1 or both copies of the GIF gene in all subjects, with additional changes observed in 2 patients.

Evidence strength: Molecular genetic evidence for congenital IF deficiency is well-documented but the condition is rare; studies are necessarily limited to small case series and molecular analyses.

5.5 Imerslund-Gräsbeck Syndrome (Cubam Receptor Deficiency)

A condition related to, but distinct from, intrinsic factor deficiency is the Imerslund-Gräsbeck syndrome (IGS), which illustrates the receptor side of the IF-B12 absorption pathway. Imerslund-Gräsbeck syndrome (IGS) or selective vitamin B12 (cobalamin) malabsorption with proteinuria is a rare autosomal recessive disorder characterised by vitamin B12 deficiency commonly resulting in megaloblastic anemia, which is responsive to parenteral vitamin B12 therapy and appears in childhood. IGS is caused by a selective incapacity to transport vitamin B12 across the intestinal wall, and is not related to a lack of gastric intrinsic factor. The cause is a defect in the receptor of the vitamin B12-intrinsic factor complex of the ileal enterocyte. In most cases, the molecular basis of the selective malabsorption and proteinuria involves a mutation in one of two genes, cubilin (CUBN) on chromosome 10 or amnionless (AMN) on chromosome 14. The syndrome was first described in Finland and Norway where the prevalence is about 1:200,000.

5.6 Post-Surgical B12 Deficiency (Gastrectomy and Bariatric Surgery)

Patients undergoing proximal gastric resection or total gastrectomy and those with pernicious anemia require parenteral injections of vitamin B12. Other risk factors contributing to pernicious anemia are anything that damages or removes a portion of the stomach's parietal cells, including bariatric surgery, gastric tumours, gastric ulcers, and excessive consumption of alcohol.

Total gastrectomy for cure of upper body cancer of stomach is gradually growing in Korea and Japan, and more than 50% of the patients are reported to have deficiency of vitamin B12. A clinical trial (NCT00699478) was registered specifically to evaluate whether oral B12 administration could compensate for the complete absence of IF following total gastrectomy, highlighting that while passive absorption at high doses may be possible, the standard clinical approach remains parenteral supplementation.

Evidence strength: Mechanistic evidence is strong. Clinical practice is established based on cohort and case data; the specific use of exogenous oral IF concentrate in post-gastrectomy patients has historical support but limited modern RCT evidence.

6. Body Systems and Health Areas

• Gastrointestinal / Absorptive: Intrinsic factor is the central mediator of active vitamin B12 absorption from the terminal ileum. Any disruption of its production, function, or receptor interaction results in systemic B12 deficiency.
• Haematological: Vitamin B12 is needed for red blood cells to form and grow. IF deficiency leads directly to megaloblastic/macrocytic anemia.
• Neurological: Vitamin B12 also has effects on nerve development and DNA synthesis. Deficiency from IF absence causes subacute combined degeneration of the spinal cord, peripheral neuropathy, and cognitive impairment.
• Cardiovascular: Insufficiency of intrinsic factor could lead to devastating consequences on body homeostasis. The effect ranges from haematological to neurological disorders and, in unfortunate cases, fatal cardiovascular disease. This is mediated through elevated homocysteine resulting from impaired methionine synthase activity.
• DNA Synthesis and Cell Division: Vitamin B12 is an essential nutrient that the body requires for two major processes: the synthesis of DNA and the proper function of nerve cells through the maintenance of the myelin sheath.
• Renal (secondary): In Imerslund-Gräsbeck syndrome (a condition of defective IF receptor function), mild proteinuria without kidney disease is documented in about half of affected individuals due to impaired tubular protein reabsorption by the cubam receptor.

7. Dosage Forms and Preparations

Intrinsic factor is available in a number of forms, both as a stand-alone pharmaceutical ingredient and as part of combination preparations:

• Oral concentrate from porcine gastric/duodenal mucosa: The traditional preparation. Haematinic concentrate with intrinsic factor is a multifactor preparation effective in the treatment of anaemias that respond to oral haematinics, including pernicious anemia and other megaloblastic anaemias and also iron-deficiency anemia. Therapeutic quantities of haematopoietic factors that are known to be important are present in the recommended daily dose. The dosage reported in older clinical literature was one capsule twice a day (two capsules daily produce a standard response in the average uncomplicated case of pernicious anemia).
• Combination supplement capsules (porcine organ concentrates): Dietary supplement products marketed in the United States typically combine porcine stomach, porcine duodenal substance, porcine pyloric substance, and porcine pancreatic enzyme concentrate as sources of intrinsic factor, co-formulated with vitamin B12 (as cyanocobalamin) and folate.
• High-dose oral cyanocobalamin (bypassing IF-mediated absorption): For patients with IF deficiency, the literature documents use of oral vitamin B12 replacement at 1000 mcg daily as adequate to replace vitamin B12 levels in patients with pernicious anemia. In patients with a deficiency in intrinsic factors, either due to pernicious anemia or gastric bypass surgery, a parenteral dose of B12 is recommended, as oral B12 will not be fully absorbed due to the lack of intrinsic factors. A dose of 1000 mcg of B12 via the intramuscular route is recommended.
• Parenteral (intramuscular) B12 injection: The treatment of pernicious anemia consists of life-long replacement of vitamin B12, usually via intramuscular injections. This bypasses the requirement for intrinsic factor entirely.

Note on the dietary supplement context: Intrinsic factor derived from porcine mucosa is sold in capsule and tablet form as a dietary supplement in the United States. The assumption in these products is that exogenous animal-derived IF will supplement reduced endogenous IF production. However, the efficacy of orally ingested exogenous porcine IF in humans — particularly whether it survives gastric digestion in functional form and successfully facilitates B12 absorption — has limited direct modern clinical trial evidence. Older studies from the 1950s–1970s supported its clinical utility in maintaining pernicious anemia remission, but this literature predates modern trial standards.

8. Safety Considerations and Drug Interactions

8.1 Autoimmune Antibody Development Against Exogenous IF

A historically documented safety concern with oral porcine or bovine intrinsic factor preparations is the development of antibodies to the animal-derived IF over time. This was documented in the mid-twentieth century when oral IF concentrates were used more widely; patients who initially responded to such preparations could lose response as antibodies formed against the foreign protein, necessitating switch to parenteral B12 therapy. This phenomenon represents a specific concern with exogenous IF supplementation that does not apply to simple oral B12 dosing.

8.2 Drug Interactions Affecting Intrinsic Factor Function

A clinically important area of pharmacology concerns the multiple drug classes that disrupt the IF-mediated B12 absorption pathway:

• Proton pump inhibitors (PPIs): PPIs reduce gastric acid secretion, and as a result affect the release of vitamin B12 from intake through impairing intrinsic factor release. PPIs work by blocking gastric H+K+-ATPase, which is responsible for pumping H+ ions from within gastric parietal cells into the gastric lumen, where they react with Cl- ions to form hydrochloric acid. H2RAs work by inhibiting the interaction of histamine with the parietal cell histamine H2 receptor. This blocks a cAMP-dependent pathway that promotes H+K+-ATPase function, thus reducing gastric acid production. A lack of gastric acid and pepsin decreases the release of vitamin B-12 from proteins in food and thus reduces its availability for absorption in the ileum.
• Metformin: Metformin likely affects vitamin B-12 absorption by interfering with Ca2+, which is required for the IF-mediated absorption of vitamin B-12 via the cubulin-amnionless IF receptor in the ileum. Additional mechanisms include: impaired enterohepatic circulation of vitamin B12, increased hepatic storage, reduced intrinsic factor (IF) production, decreased intestinal motility with bacterial overgrowth, and calcium interference hindering the binding of the IF-vitamin B12 complex to ileal receptors, thereby reducing vitamin B12 absorption.
• Combination of metformin and PPIs: Metformin and PPIs are frequently co-prescribed, raising concern for additive or synergistic risk of vitamin B12 deficiency. Reported prevalence rates support this, with 21.91% in metformin monotherapy, 25.58% in PPI monotherapy, and 34.15% in combination therapy.
• H2-receptor antagonists (H2RAs): IF secretion is inhibited by H2 receptor antagonists. H2RAs work by inhibiting the interaction of histamine with the parietal cell histamine H2 receptor. This blocks a cAMP-dependent pathway that promotes H+K+-ATPase function, thus reducing gastric acid production.
• Alcohol: Other risk factors contributing to pernicious anemia are anything that damages or removes a portion of the stomach's parietal cells, including bariatric surgery, gastric tumours, gastric ulcers, and excessive consumption of alcohol.
• Nitrous oxide: Vitamin B12 deficiency may be due to a dietary deficiency, malabsorption due to lack of intrinsic factor or parietal cells, or inhalation of nitrous oxide. While nitrous oxide does not directly impair IF, it oxidatively inactivates the vitamin B12 that IF-mediated absorption delivers.

8.3 Conditions That Reduce Intrinsic Factor Production or Function

Because efficient vitamin B12 absorption in humans is dependent on intrinsic factor, diseases that reduce intrinsic factor secretion (e.g., atrophic gastritis), interfere with cleavage of the binding proteins (e.g., pancreatic exocrine insufficiency), or decrease binding and absorption of the intrinsic factor-vitamin B12 complex (e.g., ileal disease or resection) can result in this type of anaemia.

Other autoimmune disorders, especially thyroid disease, diabetes mellitus, and vitiligo, are also commonly associated with pernicious anemia. Studies show that high homology exists between the beta subunit of parietal cell antibody (PCA) and that of H. pylori urease, suggesting that the autoimmune trigger is mediated by molecular mimicry due to long-standing H. pylori infection.

8.4 Gastric Cancer Risk in Long-Standing IF Deficiency

When pernicious anemia remains undiagnosed and untreated for an extended period, it may lead to neurological complications, gastric cancer, and even fatal anemia. The atrophic gastritis associated with pernicious anemia confers an increased risk of gastric adenocarcinoma and gastric carcinoid tumours, independent of the IF deficiency per se.

8.5 Porcine-Derived Supplement Considerations

Exogenous intrinsic factor of porcine origin present in dietary supplements is derived from animal mucosa. Individuals with religious dietary restrictions regarding pork products (e.g., observant Jews, Muslims) would need to consider alternative B12 supplementation strategies. Additionally, individuals with allergies to porcine-derived proteins should exercise appropriate caution.

References

• StatPearls: Physiology, Gastric Intrinsic Factor — NCBI Bookshelf (NIH)
• StatPearls: Pernicious Anemia — NCBI Bookshelf (NIH)
• StatPearls: Vitamin B12 Deficiency — NCBI Bookshelf (NIH)
• StatPearls: Pernicious Anemia (Nursing) — NCBI Bookshelf (NIH)
• Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia — PMC / Frontiers in Medicine (2016)
• Oral vitamin B12 supplementation in pernicious anemia: a prospective cohort study — American Journal of Clinical Nutrition (2024)
• Proton Pump Inhibitors, H2-Receptor Antagonists, Metformin, and Vitamin B-12 Deficiency: Clinical Implications — PMC / Advances in Nutrition (2018)
• Metformin With Either Histamine H2-Receptor Antagonists or Proton Pump Inhibitors: Neuropathy via Vitamin B12 Depletion — PMC
• Human gastric intrinsic factor expression is not restricted to parietal cells — PMC / Journal of Anatomy (1996)
• Imerslund-Gräsbeck syndrome (selective vitamin B12 malabsorption with proteinuria) — PMC / Orphanet Journal of Rare Diseases (2006)
• Imerslund-Gräsbeck Syndrome — NIH GARD (Genetic and Rare Diseases Information Center)
• CBLIF (GIF) Gene Entry *609342 — OMIM
• Imerslund-Gräsbeck Syndrome 1 (IGS1) Entry 261100 — OMIM
• Intrinsic factor — Wikipedia (with cited primary literature)
• Intrinsic Factor: An overview — ScienceDirect Topics
• Intrinsic factor — MedlinePlus Medical Encyclopedia (NIH/NLM)
• Intrinsic factor — Encyclopaedia Britannica
• Vitamin B12-Deficiency Anemia — NHLBI, NIH
• Inherited and acquired vitamin B12 deficiencies: Which administration route to choose for supplementation? — Frontiers in Pharmacology (2022)
• William B. Castle and Intrinsic Factor — Annals of Internal Medicine (1978)
• William B. Castle and intrinsic factor (abstract) — PubMed
• Intrinsic Factor — New England Journal of Medicine (1964)
• B12 (Liver-Stomach Concentrate With Intrinsic Factor): Uses, Dosage, Interactions — RxList
• Risk of Vitamin B12 Deficiency Associated with Proton Pump Inhibitors, Metformin, and H2 Blockers in Geriatric Patients — Egyptian Journal of Internal Medicine / Springer (2025)
• Vitamin B12 Deficiency Associated with Metformin and Proton Pump Inhibitors: Disproportionality and Interaction Analysis — Diseases (MDPI, 2025)
• Intrinsic factor (comprehensive overview with primary citations) — Grokipedia